Protein aggregation: A perspective from amyloid and inclusion-body formation

Current Science

Volumn 92, Issue 6, 2007, Pages 758-767

  Idicula Thomas, Susan ^a   Balaji, Petety V ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

Folding intermediates; Molecular evolution; Natively unfolded; Protein folding

Indexed keywords

EID: 34147190404     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Uversky, V. N. and Fink, A. L., Conformational constraints for amyloid fibrillation: The importance of being unfolded. Biochim. Biophys. Acta, 2004, 1698, 131-153.
2. Fink, A. L., Protein aggregation: Folding aggregates, inclusion bodies and amyloid. Fold Des., 1998, 3, R9-R23.
3. Ventura, S., Sequence determinants of protein aggregation: Tools to increase protein solubility. Microb. Cell Fact., 2005, 4, 11.
4. Rousseau, F., Schymkowitz, J. and Serrano, L., Protein aggregation and amyloidosis: Confusion of the kinds?. Curr. Opin. Struct. Biol., 2006, 16, 118-126.
5. Hirschfield, G. M., Amyloidosis: A clinico-pathophysiological synopsis. Semin. Cell Dev. Biol., 2004, 15, 39-44.
6. Murzin, A. G., Brenner, S. E., Hubbard, T. and Chothia, C., SCOP: A structural classification of proteins database for the investigation of sequences and structures. J. Mol. Biol., 1995, 247, 536-540.
7. Buxbaum, J. N., Diseases of protein conformation: What do in vitro experiments tell us about in vivo diseases?. Trends Biochem. Sci., 2003, 28, 585-592.
8. Pieri, L., Bucciantini, M., Nosi, D., Formigli, L., Savistchenko, J., Melki, R. and Stefani, M., The yeast prion Ure2p native-like assemblies are toxic to mammalian cells regardless to their aggregation state. J. Biol. Chem., 2006, 281, 15337-15344.
9. Scheibel, T. and Buchner, J., Protein aggregation as a cause for disease. Handb. Exp. Pharmacol., 2006, 172, 199-219.
10. Kirschner, D. A., Elliott-Bryant, R., Szumowski, K. E., Gonnerman, W. A., Kindy, M. S., Sipe, J. D. and Cathcart, E. S., In vitro amyloid fibril formation by synthetic peptides corresponding to the amino terminus of apoSAA isoforms from amyloid-susceptible and amyloid-resistant mice. J. Struct. Biol., 1998, 124, 88-98.
11. Tabner, B. J., El-Agnaf, O. M., German, M. J., Fullwood, N. J. and Allsop, D., Protein aggregation, metals and oxidative stress in neurodegenerative diseases. Biochem. Soc. Trans., 2005, 33, 1082-1086.
12. Pedelacq, J. D. et al., Engineering soluble proteins for structural genomics. Nature Biotechnol., 2002, 20, 927-932.
13. Lilie, H., Schwarz, E. and Rudolph, R., Advances in refolding of proteins produced in E. coli. Curr. Opin. Biotechnol., 1998, 9, 497-501.
14. Makrides, S. C., Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol. Rev., 1996, 60, 512-538.
15. Singh, S. M. and Panda, A. K., Solubilization and refolding of bacterial inclusion body proteins. J. Biosci. Bioeng., 2005, 99, 303-310.
16. Schrodel, A. and de Marco, A., Characterization of the aggregates formed during recombinant protein expression in bacteria. BMC Biochem., 2005, 6, 10.
17. Oberg, K., Chrunyk, B. A., Wetzel, R. and Fink, A. L., Native-like secondary structure in interleukin-1 beta inclusion bodies by attenuated total reflectance FTIR. Biochemistry, 2005, 33, 2628-2634.
18. Tokatlidis, K., Dhurjati, P., Millet, J., Beguin, P. and Aubert, J. P., High activity of inclusion bodies formed in Escherichia coli overproducing Clostridium thermocellum endoglucanase D. FEBS Lett., 1991, 282, 205-208.
19. Worrall, D. M. and Goss, N. H., The formation of biologically active beta-galactosidase inclusion bodies in Escherichia coli. Aust. J. Biotechnol., 1989, 3, 28-32.
20. Garcia-Fruitos, E. et al., Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microb. Cell Fact., 2005, 4, 27.
21. Bowden, G. A., Paredes, A. M. and Georgiou, G., Structure and morphology of protein inclusion bodies in Escherichia coli. Biotechnology, 1991, 9, 725-730.
22. Przybycien, T. M., Dunn, J. P., Valax, P. and Georgiou, G., Secondary structure characterization of beta-lactamase inclusion bodies. Protein Eng., 1994, 7, 131-136.
23. Carrio, M., Gonzalez-Montalban, N., Vera, A., Villaverde, A. and Ventura, S., Amyloid-like properties of bacterial inclusion bodies. J. Mol. Biol., 2005, 347, 1025-1037.
24. Clark, E. D. B., Protein refolding for industrial purposes. Curr. Opin. Biotechnol., 2001, 12, 202-207.
25. Jurgen, B., Hanschke, R., Sarvas, M., Hecker, M. and Schweder, T., Proteome and transcriptome based analysis of Bacillus subtilis cells overproducing an insoluble heterologous protein. Appl. Microbiol. Biotechnol., 2001, 55, 326-332.
26. Lindwall, G., Chau, M., Gardner, S. R. and Kohlstaedt, L. A., A sparse matrix approach to the solubilization of overexpressed proteins. Protein Eng., 2000, 13, 67-71.
27. Dziewulska, D. and Rafalowska, J., Proteinaceous intracellular inclusions in neurodegenerative disorders. Folia Neuropathol., 2005, 43, 51-63.
28. Dobson, C. M., Principles of protein folding, misfolding and aggregation. Semin. Cell Dev. Biol., 2004, 15, 3-16.
29. Dobson, C. M., Protein misfolding, evolution and disease. Trends Biochem. Sci., 1999, 24, 329-332.
30. Makin, O. S. and Serpell, L. C., Structures for amyloid fibrils. FEBS J., 2005, 272, 5950-5961.
31. Nelson, R., Sawaya, M. R., Balbirnie, M., Madsen, A. O., Riekel, C., Grothe, R. and Eisenberg, D., Structure of the cross-beta spine of amyloid-like fibrils. Nature, 2005, 435, 773-778.
32. Luehrs, T. et al., 3D structure of Alzheimer's amyloid-beta (1-42) fibrils. Proc. Natl. Acad. Sci. USA, 2005, 102, 17342-17347.
33. Tycko, R., Progress towards a molecular-level structural understanding of amyloid fibrils. Curr. Opin. Struct. Biol., 2004, 14, 96-103.
34. Pickersgill, R., Jenkins, J., Harris, G., Nasser, W. and Robert-Baudouy, J., The structure of Bacillus subtilis pectate lyase in complex with calcium. Nature Struct. Mol. Biol., 1994, 1, 717-723.
35. Ma, B. and Nussinov, R., Stabilities and conformations of Alzheimer's beta-amyloid peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): Sequence effects. Proc. Natl. Acad. Sci. USA, 2002, 99, 14126-14131.
36. Liu, Y., Gotte, G., Libonati, M. and Eisenberg, D., Structures of the two 3D domain-swapped RNase A trimers. Protein Sci., 2002, 11, 371-380.
37. Tattum, M. H. et al., Elongated oligomers assemble into mammalian PrP amyloid fibrils. J. Mol. Biol., 2006, 357, 975-985.
38. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W. and Glabe, C. G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300, 486-489.
39. Ma, B. and Nussinov, R., Molecular dynamics simulations of alanine rich beta-sheet oligomers: Insight into amyloid formation. Protein Sci., 2002, 11, 2335-2350.
40. Balbirnie, M., Grothe, R. and Eisenberg, D. S., An amyloid-forming peptide from the yeast prion Sup35 reveals a dehydrated beta-sheet structure for amyloid. Proc. Natl. Acad. Sci. USA, 2001, 98, 2375-2380.
41. Zanuy, D., Haspel, N., Tsai, H. H., Ma, B., Gunasekaran, K., Wolfson, H. J. and Nussinov, R., Side chain interactions determine the amyloid organization: A single layer beta-sheet molecular structure of the calcitonin peptide segment 15-19. Phys. Biol., 2004, 1, 89-99.
42. Bucciantini, M. et al., Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature, 2002, 416, 507-511.
43. Johansson, J., Molecular determinants for amyloid fibril formation: Lessons from lung surfactant protein C. Swiss Med. Wkly., 2003, 133, 275-282.
44. Uversky, V. N., Protein folding revisited. A polypeptide chain at the folding-misfolding-nonfolding cross-roads: Which way to go?. Cell. Mol. Life Sci., 2003, 60, 1852-1871.
45. Kallberg, Y., Gustafsson, M., Persson, B., Thyberg, J. and Johansson, J., Prediction of amyloid fibril-forming proteins. J. Biol. Chem., 2001, 276, 12945-12950.
46. Idicula-Thomas, S. and Balaji, P. V., Understanding the relationship between the primary structure of proteins and their amyloidogenic propensity: Clues from inclusion body formation. Prot. Eng. Des. Sel., 2005, 18, 175-180.
47. Viguera, A. R., Villegas, V., Aviles, F. X. and Serrano, L., Favourable native-like helical local interactions can accelerate protein folding. Fold. Des., 1997, 2, 23-33.
48. Ohnishi, S. and Takano, K., Amyloid fibrils from the viewpoint of protein folding. Cell Mol. Life Sci., 2004, 61, 511-524.
49. Jahn, T. R. and Radford, S. E., The Yin and Yang of protein folding. FEBS J., 2005, 272, 5962-5970.
50. Chiti, F., Stefani, M., Taddei, N., Ramponi, G. and Dobson, C. M., Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature, 2003, 424, 805-808.
51. Boeggeman, E. E., Ramakrishnan, B. and Qasba, P. K., The N-terminal stem region of bovine and human beta 1,4-galactosyltransferase I increases the in vitro folding efficiency of their catalytic domain from inclusion bodies. Protein Exp. Purif., 2003, 30, 219-229.
52. Sati, S. P., Singh, S. K., Kumar, N. and Sharma, A., Extra terminal residues have a profound effect on the folding and solubility of a Plasmodium falciparum sexual stage-specific protein overexpressed in Escherichia coli. Eur. J. Biochem., 2002, 269, 5259-5263.
53. Goldsbury, C. et al., Amyloid fibril formation from full-length and fragments of amylin. J. Struct. Biol., 2000, 130, 352-362.
54. Jones, S., Manning, J., Kad, N. M. and Radford, S. E., Amyloid-forming peptides from beta 2-microglobulin - Insights into the mechanism of fibril formation in vitro. J. Mol. Biol., 2003, 325, 249-257.
55. King, J., Haase-Pettingell, C., Robinson, A. S., Speed, M. and Mitraki, A., Thermolabile folding intermediates: Inclusion body precursors and chaperonin substrates. FASEB J., 1996, 10, 57-66.
56. Yon, J. M., Protein folding in the post-genomic era. J. Cell Mol. Med., 2002, 6, 307-327.
57. Horwich, A., Protein aggregation in disease: A role for folding intermediates forming specific multimeric interactions. J. Clin. Invest., 2002, 110, 1221-1232.
58. Zhang, Y., Olsen, D. R., Nguyen, K. B., Olson, P. S., Rhodes, E. T. and Mascarenhas, D., Expression of eukaryotic proteins in soluble form in Escherichia coli. Protein Exp. Purif., 1998, 12, 159-165.
59. Mogk, A., Mayer, M. P. and Deuerling, E., Mechanisms of protein folding: Molecular chaperones and their application in biotechnology. Chembiochem., 2002, 3, 807-814.
60. Komar, A. A., Lesnik, T. and Reiss, C., Synonymous codon substitutions affect ribosome traffic and protein folding during in vitro translation. FEBS Lett., 1999, 462, 387-391.
61. Davis, G. D., Elisee, C., Newham, D. M. and Harrison, R. G., New fusion protein systems designed to give soluble expression in Escherichia coli. Biotechnol. Bioeng., 1999, 65, 382-388.
62. Bertone, P. et al., SPINE: An integrated tracking database and data mining approach for identifying feasible targets in high-throughput structural proteomics. Nucleic Acids Res., 2001, 29, 2884-2898.
63. Luan, C. H. et al., 2004. High-throughput expression of C. elegans proteins. Genome Res., 14, 2102-2110.
64. Idicula-Thomas, S. and Balaji, P. V., Understanding the relationship between the primary structure of proteins and their propensity to be soluble on overexpression in Escherichia coli. Protein Sci., 2005, 14, 582-592.
65. Idicula-Thomas, S., Kulkarni, A. J., Kulkarni, B. D., Jayaraman, V. K. and Balaji, P. V., A support vector machine-based method for predicting the propensity of a protein to be soluble or to form inclusion body on over-expression in Escherichia coli. Bioinformatics, 2006, 22, 278-284.
66. Zerovnik, E., Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease. Eur. J. Biochem., 2002, 269, 3362-3371.
67. DuBay, K. F., Pawar, A. P., Chiti, F., Zurdo, J., Dobson, C. M. and Vendruscolo, M., Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. J. Mol. Biol., 2004, 341, 1317-1326.
68. Wurth, C., Kim, W. and Hecht, M. H., Combinatorial approaches to probe the sequence determinants of protein aggregation and amyloidogenicity. Protein Pept. Lett., 2006, 13, 279-286.
69. Fernandez, A., Kardos, J., Scott, L. R., Goto, Y. and Berry, R. S., Structural defects and the diagnosis of amyloidogenic propensity. Proc. Natl. Acad. Sci. USA, 2003, 100, 6446-6451.
70. Alexandrescu, A. T., Amyloid accomplices and enforcers. Protein Sci., 2005, 14, 1-12.
71. Wetzel, R., Perry, L. J. and Veilleux, C., Mutations in human interferon gamma affecting inclusion body formation identified by a general immunochemical screen. Biotechnology, 1991, 9, 731-737.
72. Clark, E. D. B., Refolding of recombinant proteins. Curr. Opin. Biotechnol., 1998, 9, 157-163.
73. Georgiou, G. and Valax, P., Isolating inclusion bodies from bacteria. Methods Enzymol., 1999, 309, 48-58.
74. Rudolph, R., Renaturation of recombinant, disulfide-bonded proteins from inclusion bodies. In Modern Methods in Protein and Nucleic Acid Research (ed. Tschesche, H.), Walter de Gruyter, Berlin, 1990, pp. 149-172.
75. Chen, J., Acton, T. B., Basu, S. K., Montelione, G. T. and Inouye, M., Enhancement of the solubility of proteins overexpressed in Escherichia coli by heat shock. J. Mol. Microbiol. Biotechnol., 2002, 4, 519-524.
76. Winter, J., Neubauer, P., Glockshuber, R. and Rudolph, R., Increased production of human proinsulin in the periplasmic space of Escherichia coli by fusion to DsbA. J. Biotechnol., 2001, 84, 175-185.
77. Nygaard, F. B. and Harlow, K. W., Heterologous expression of soluble, active proteins in Escherichia coli: The human estrogen receptor hormone-binding domain as paradigm. Protein Exp. Purif., 2001, 21, 500-509.
78. Tandon, S. and Horowitz, P., The effects of lauryl maltoside on the reactivation of several enzymes after treatment with guanidinium chloride. Biochim. Biophys. Acta, 1988, 955, 19-25.
79. Katzav-Gozansky, T., Hanan, E. and Solomon, B., Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation. Biotechnol. Appl. Biochem., 1996, 23, 227-230.
80. Schein, C. H. and Noteborn, M. H. M., Formation of soluble recombinant proteins in Escherichia coli is favored by lower growth temperature. Biotechnology, 1988, 6, 291-294.
81. Jenkins, T. M., Hickman, A. B., Dyda, F., Ghirlando, R., Davies, D. R. and Craigie, R., Catalytic domain of human immunodeficiency virus type 1 integrase: Identification of a soluble mutant by systematic replacement of hydrophobic residues. Proc. Natl. Acad. Sci. USA, 1995, 92, 6057-6061.
82. Sachdev, D. and Chirgwin, J. M., Solubility of proteins isolated from inclusion bodies is enhanced by fusion to maltose-binding protein or thioredoxin. Protein Exp. Purif., 1998, 12, 122-132.
83. Hammarstrom, M., Hellgren, N., van Den Berg, S., Berglund, H. and Hard, T., Rapid screening for improved solubility of small human proteins produced as fusion proteins in Escherichia coli. Protein Sci., 2002, 11, 313-321.
84. Knaust, R. K. and Nordlund, P., Screening for soluble expression of recombinant proteins in a 96-well format. Anal. Biochem., 2001, 297, 79-85.
85. Lesley, S. A., Graziano, J., Cho, C. Y., Knuth, M. W. and Klock, H. E., Gene expression response to misfolded protein as a screen for soluble recombinant protein. Protein Eng., 2002, 15, 153-160.
86. Shih, Y. P., Kung, W. M., Chen, J. C., Yeh, C. H., Wang, A. H. and Wang, T. F., High-throughput screening of soluble recombinant proteins. Protein Sci., 2002, 11, 1714-1719.
87. Wigley, W. C., Stidham, R. D., Smith, N. M., Hunt, J. F. and Thomas, P. J., Protein solubility and folding monitored in vivo by structural complementation of a genetic marker protein. Nature Biotechnol., 2001, 19, 131-136.
88. Waldo, G. S., Genetic screens and directed evolution for protein solubility. Curr. Opin. Chem. Biol., 2003, 7, 33-38.
89. Tjernberg, L. O. et al., Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem., 1996, 271, 8545-8548.
90. Solomon, B., Anti-aggregating antibodies, a new approach towards treatment of conformational diseases. Curr. Med. Chem., 2002, 9, 1737-1749.
91. Tanaka, M., Machida, Y. and Nukina, N., A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules. J. Mol. Med., 2005, 83, 343-352.
92. Villegas, V., Zurdo, J., Filimonov, V. V., Aviles, F. X., Dobson, C. M. and Serrano, L., Protein engineering as a strategy to avoid formation of amyloid fibrils. Protein Sci., 2000, 9, 1700-1708.
93. Clark, E. D. B., Schwarz, E. and Rudolph, R., Inhibition of aggregation side reactions during in vitro protein folding. Methods Enzymol., 1999, 309, 217-236.
94. Ventura, S. and Villaverde, A., Protein quality in bacterial inclusion bodies. Trends Biotechnol., 2006, 24, 179-185.
95. Dinner, A. R., Sali, A., Smith, L. J., Dobson, C. M. and Karplus, M., Understanding protein folding via free-energy surfaces from theory and experiment. Trends Biochem. Sci., 2000, 25, 331-339.
96. Papp, E., Nardai, G., Soti, C. and Csermely, P., Molecular chaperones, stress proteins and redox homeostasis. Biofactors, 2003, 17, 249-257.
97. Zhang, K. and Kaufman, R. J., The unfolded protein response: A stress signaling pathway critical for health and disease. Neurology, 2006, 66, S102-S109.
98. Jacobsen, J. S., Reinhart, P. and Pangalos, M. N., Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx., 2005, 2, 612-626.
99. Jain, S., Wood, N. W. and Healy, D. G., Molecular genetic pathways in Parkinson's disease: A review. Clin. Sci., 2005, 109, 355-364.
100. Bratosiewicz-Wasik, J., Wasik, T. J. and Liberski, P. P., Molecular approaches to mechanisms of prion diseases. Folia Neuropathol., 2004, 42 Suppl. A, 33-46.
101. Welch, W. J. Role of quality control pathways in human diseases involving protein misfolding. Semin. Cell Dev. Biol., 2004, 15, 31-38.
102. Pey, A. L., Desviat, L. R., Gamez, A., Ugarte, M. and Perez, B., Phenylketonuria: Genotype-phenotype correlations based on expression analysis of structural and functional mutations in PAH. Hum. Mutat., 2003, 21, 370-378.
103. Whiteman, P., Hutchinson, S. and Handford, P. A., Fibrillin-1 misfolding and disease. Antioxid. Redox Signal., 2006, 8, 338-346.
104. Gajko-Galicka, A., Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Acta Biochim. Pol., 2002, 49, 433-441.
105. Schnog, J. B., Duits, A. J., Muskiet, F. A., ten Cate, H., Rojer, R. A. and Brandjes, D. P., Sickle cell disease: A general overview. Neth. J. Med., 2004, 62, 364-374.
106. Montalvo, A. L. et al., Molecular analysis of the HEXA gene in Italian patients with infantile and late onset Tay-Sachs disease: detection of fourteen novel alleles. Hum. Mutat., 2005, 26, 282.
107. Merlini, G. and Bellotti, V., Lysozyme: A paradigmatic molecule for the investigation of protein structure, function and misfolding. Clin. Chim. Acta, 2005, 357, 168-172.
108. Larson, J. L. and Miranker, A. D., The mechanism of insulin action on islet amyloid polypeptide fiber formation. J. Mol. Biol., 2004, 335, 221-231.
109. Carrell, R. W. and Lomas, D. A., Alpha1-antitrypsin deficiency - a model for conformational diseases. N. Engl. J. Med., 2002, 346, 45-53.
110. Radford, S. E., Gosal, W. S. and Platt, G. W., Towards an understanding of the structural molecular mechanism of b(2)-microglobulin amyloid formation in vitro. Biochim. Biophys. Acta, 2005, 1753, 51-63.
111. Mussap, M. and Plebani, M., Biochemistry and clinical role of human cystatin C. Crit. Rev. Clin. Lab. Sci., 2004, 41, 467-550.
112. Mendes, H. F., van der Spuy, J., Chapple, J. P. and Cheetham, M. E., Mechanisms of cell death in rhodopsin retinitis pigmentosa: Implications for therapy. Trends Mol. Med., 2005, 11, 177-185.
113. Sandilands, A. et al., Altered aggregation properties of mutant gamma-crystallins cause inherited cataract. EMBO J., 2002, 21, 6005-6014.
114. Otto, M., Hansen, T. and Kriegsmann, J., Images in cardiology: Intracellular cardiac amyloidosis in familiar amyloid polyneuropathy of the Portuguese type. Heart, 2002, 88, 90.
115. Eriksson, L. and Westermark, P., Characterization of intracellular amyloid fibrils in the human choroid plexus epithelial cells. Acta Neuropathol., 1990, 80, 597-603.